How to Get Started With Wegovy and Foundayo GLP-1 Weight Loss Pills

Wegovy and Foundayo GLP-1 Weight Loss Pills: What to Know Before You Get Started

Wegovy and Foundayo GLP-1 Weight Loss Pills: What to Know Before You Get Started
Adobe Stock (2)

Shifting from weekly glucagon-like peptide-1 (GLP-1) receptor agonist injections to a daily oral medication may be a game-changer for people looking to lose weight, especially those who feel hesitant about using needles. Orforglipron (Foundayo) and semaglutide (Wegovy) tablets are viable alternatives to injectable options that may be more convenient to take.

Obesity medicine physicians explain what you need to know if you’re considering going on one of these new oral weight loss medications.

Who Are GLP-1 Weight Loss Pills For?

GLP-1 weight loss pills aren’t for everyone. Only certain people are medically indicated to take the new pills.

Orforglipron (Foundayo) is intended for adults who are overweight or have obesity and at least one other weight-related condition, such as hypertension (high blood pressure) or dyslipidemia (high cholesterol).

Semaglutide (Wegovy) tablets are intended for people over age 12 who have obesity, as well as adults who are overweight and have at least one other weight-related condition. Wegovy pills can also be prescribed to people with a history of heart attack or stroke, as well as those with symptomatic peripheral arterial disease.

Each medication is designed to be taken in combination with a reduced-calorie diet and regular exercise.

In addition to these clinical indications, experts see these weight loss pills being most useful in certain circumstances, says Atlanta-based Reema Dbouk, MD, a spokesperson for the Obesity Society. According to Dr. Dbouk, they can be particularly helpful for people who:

  • Reached their goal weight and are now in a maintenance phase
  • Feel uncomfortable using injectable medication
  • Travel often and need a more convenient option

How Do GLP-1 Pills Work?

“Oral and injectable weight loss medications are in the same pharmacological class of medication — they are all GLP-1s, which mimic the GLP-1 hormone that regulates hunger,” says Dhvani Doshi, MD, MPH, the medical director and an obesity medicine physician at University Hospital in Newark, New Jersey.

GLP-1 pills work by helping you consume fewer calories, leading to weight loss. “Similar to injectable GLP-1 medications, oral options decrease appetite and slow the movement of food out of the stomach so that one feels full quicker,” says Dbouk.

Oral and injectable GLP-1s primarily differ in how they’re absorbed in the body, says Dr. Doshi. When you take a daily oral pill, you maintain a steady dose of the medication in your body throughout the week. On the other hand, injectable GLP-1s are administered once per week, and the medication can wear off by the end of the seven-day period. Some people who are especially sensitive to small changes in this hormone may notice increased hunger by the end of the week, says Doshi.

Research shows that people taking a 25 milligram (mg) dose of oral semaglutide (the highest available) daily lost an average of 13.6 percent of their body weight after 64 weeks, compared with 2.2 percent of body weight loss in the placebo group.

 Meanwhile, the highest daily dose of orforglipron led to an average of 11.1 percent body weight loss after 72 weeks, compared with 2.1 percent body weight loss in the placebo group.

Dosage and Administration

Foundayo and the Wegovy pill come in a variety of doses, but no matter your weight loss goal, you’ll likely start with a lower dose and increase from there, unless otherwise indicated by your physician.

Foundayo tablets are available in the following doses:

  • 0.8 mg
  • 2.5 mg
  • 5.5 mg
  • 9 mg
  • 14.5 mg
  • 17.2 mg

Most people begin with 0.8 mg once daily. After 30 days, you may increase to the next dose with physician guidance and approval.

The Wegovy pill is available in the following doses:

  • 1.5 mg
  • 4 mg
  • 9 mg
  • 25 mg

Most people begin with 1.5 mg once daily. After 30 days, you may increase to the next dose with physician guidance and approval, continuing until you reach your maintenance dose.

As for administration, one whole oral Wegovy tablet must be taken on an empty stomach in the morning with up to 4 ounces (oz) of water. You must then wait at least 30 minutes to eat, drink, or take other medications. Not following these instructions exactly can impact how well the medication is absorbed.

Foundayo is decidedly less finicky. “Orforglipron can be taken with food, water, or other medications,” says Eric Nolen-Doerr, MD, an endocrinologist and a weight management specialist at Boston Medical Center in Massachusetts. Its small-molecule structure remains stable as it passes through the gastrointestinal system, allowing for better absorption and eliminating the need for the administration “rules” that apply to oral semaglutide.

Side Effects

When it comes to side effects, there doesn’t seem to be a big difference between the two pills, or between GLP-1 pills and injections.

Side effects are typically mild, but they can still impact your daily quality of life. The most common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain. Additional side effects include:

  • Abdominal distension
  • Bloating
  • Burping
  • Changes in skin sensations
  • Fatigue
  • Flatulence
  • Hair loss
  • Headache
  • Indigestion
  • Low blood sugar if you have type 2 diabetes
  • Reflux
  • Stomach flu
Since these medications are new, awareness of side effects may change over time. “We’re still getting to know these oral medications in real time,” says Doshi. Overall, they’re well tolerated, but side effects may be more severe with oral medications than with their injectable counterparts.

“Eating smaller, frequent meals and avoiding heavy or greasy foods can help mitigate side effects,” says Dbouk.

Oral GLP-1 side effects are most common when you start taking the medication, as well as when you step up to a larger dose.

Optimizing Your Benefits

Experts insist that GLP-1 medications are not a magic pill, and that your lifestyle habits will greatly impact your weight loss and overall health success.

“Neither the oral nor the injectable medication work by themselves,” says Doshi. “They only truly work if you’re following a low-calorie diet and increasing your physical activity at the same time.”

With that said, oral weight loss medications can help you maintain necessary dietary changes by reducing hunger and cravings, making it easier to stick to a recommended plan. “This is what really allows for weight loss — it’s not driven by medications alone,” says Doshi.

The Takeaway

  • Oral GLP-1 medications like orforglipron (Foundayo) and semaglutide (Wegovy) tablets offer a needle-free and travel-friendly alternative to weekly weight loss injections.
  • These daily pills work by mimicking hormones that regulate hunger and slowing digestion, helping users feel full faster.
  • Administration requirements differ between the two drugs: Wegovy tablets must be taken on an empty stomach with strict timing rules, while Foundayo can be taken more flexibly with food or other medications.
  • While these pills are effective for weight loss when combined with diet and exercise, they can cause gastrointestinal side effects such as nausea and bloating, which are most common during the initial dosing phase.
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Highlights of Prescribing Information. Lilly. April 2026.
  2. Highlights of Prescribing Information. Novo Nordisk. March 2026.
  3. Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults With Overweight or Obesity. The New England Journal of Medicine. September 17, 2025.
  4. How Much Weight Loss Was Seen With Foundayo in 72-Week Clinical Trials? Drugs.com. April 23, 2026.
  5. Wharton S et al. Orfoglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. The New England Journal of Medicine. November 6, 2025.
  6. Kansakar U et al. Orfoglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes. International Journal of Molecular Sciences. January 30, 2026.
  7. Pinto M et al. Real-World Comparison of Oral Versus Injectable Semaglutide for the Reduction of Hemoglobin A1C and Weight in Patients With Type 2 Diabetes. Journal of Pharmacy Technology. November 5, 2024.
  8. Your Complete Guide to Wegovy Pill. Novo Nordisk. April 2026.

Adam Gilden, MD, MSCE

Medical Reviewer

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Me...

Jessica Migala

Author

Jessica Migala is a freelance writer with over 15 years of experience, specializing in health, nutrition, fitness, and beauty. She has written extensively about vision care, diabet...